Could one dose of bone drug be enough for breast cancer patients?

NCT ID NCT03664687

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 35 times

Summary

This study looked at whether a single dose of the bone drug zoledronate works as well as getting it every six months for three years in people with early-stage breast cancer. The goal was to see if a simpler treatment schedule could prevent bone metastases. The study enrolled 211 participants and focused on how practical it was to run the trial across multiple sites.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Juravinski Cancer Centre

    Hamilton, Ontario, L8V 5C2, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7, Canada

  • Markham Stouffville Hospital

    Markham, Ontario, L3P 7P3, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8M2, Canada

  • Southlake Regional Health Centre

    Newmarket, Ontario, L3Y 2P9, Canada

  • William Osler Health System, Brampton Civic Hospital

    Brampton, Ontario, L6R 3J7, Canada

Conditions

Explore the condition pages connected to this study.